Fig. 1
From: Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

Basic research and drug development history for PD disease and therapy. A2a adenosine receptor type 2a, mGlu metabotropic glutamate receptor, NAM negative allosteric modulator, PAM positive allosteric modulator, EDN embryonic dopamine neuron, PDDPC personalized iPSC-derived dopamine progenitor cell, iPSC induced pluripotent stem cell, DBS deep brain stimulation